Precigen (PGEN) Projected to Post Earnings on Tuesday

Precigen (NASDAQ:PGEN - Get Free Report) is expected to be issuing its quarterly earnings data before the market opens on Tuesday, March 18th. Analysts expect the company to announce earnings of ($0.06) per share and revenue of $1.30 million for the quarter.

Precigen Stock Up 3.4 %

Shares of NASDAQ PGEN traded up $0.06 during trading hours on Friday, hitting $1.80. 1,134,271 shares of the stock were exchanged, compared to its average volume of 2,037,644. The company has a market cap of $527.16 million, a PE ratio of -3.27 and a beta of 1.57. The firm has a fifty day moving average price of $1.53 and a 200-day moving average price of $1.12. Precigen has a 12 month low of $0.65 and a 12 month high of $2.17.

Analyst Upgrades and Downgrades

Several research firms recently commented on PGEN. JMP Securities reiterated a "market outperform" rating and set a $5.00 price objective on shares of Precigen in a research note on Tuesday, January 14th. HC Wainwright reissued a "buy" rating and set a $6.00 target price (up previously from $4.00) on shares of Precigen in a research report on Thursday, January 23rd. Two equities research analysts have rated the stock with a sell rating and four have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus price target of $7.00.

Precigen Company Profile

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.